Document:

Exhibit 10.2

 

SCHEDULE “A”

Stock Option Plan

 

ARTICLE 1 – DEFINITIONS AND INTERPRETATION

 

		1.1	DEFINED TERMS

 

For the purposes of this Plan, the following terms
shall have the following meanings:

 

		(a)	“Affiliate” has the meaning ascribed thereto by the Exchange;

 

		(b)	“Board” means the Board of Directors of the Corporation or, as applicable, a committee
consisting of not less than three (3) Directors of the Corporation duly appointed to administer this Plan;

 

		(c)	“Common Shares” means the common shares of the Corporation;

 

		(d)	“Company” unless specifically indicated otherwise, means a corporation, incorporated
association or organization, body corporate, partnership, trust, association or other entity other than an individual;

 

		(e)	“Consultant” means, in relation to an Corporation, an individual (other than an Employee
or a Director of the Corporation) or Company that:

 

		(i)	is engaged to provide on an ongoing bona fide basis, consulting, technical, management or other services
to the Corporation or to an Affiliate of the Corporation, other than services provided in relation to a distribution;

 

		(ii)	provides the services under a written contract between the Corporation or the Affiliate and the individual
or the Company, as the case may be;

 

		(iii)	in the reasonable opinion of the Corporation, spends or will spend a significant amount of time and attention
on the affairs and business of the Corporation or an Affiliate of the Corporation; and

 

		(iv)	has a relationship with the Corporation or an Affiliate of the Corporation that enables the individual
to be knowledgeable about the business and affairs of the Corporation,

 

and includes a Company of which a Consultant
is an employee or shareholder and a partnership of which a Consultant is an employee or partner;

 

		(f)	“Corporation” means Clearmind Medicine Inc. and its successor entities;

 

		(g)	“Director” means a director of the Corporation or of an Affiliate;

 

		(h)	“Disinterested Shareholder Approval” means the passing of an ordinary resolution by
the holders of Common Shares excluding the Common Shares held by, to the Corporation’s knowledge at the time the information is
provided, the Corporation, a Participant or an Eligible Person;

 

		(i)	“Eligible Person” means a Director, Officer, Employee or Consultant, and includes an
issuer all the voting securities of which are owned by Eligible Persons;

 

		(j)	“Employee” means an individual who:

 

		(i)	is considered an employee of the Issuer or its subsidiary under the Income Tax Act (Canada) (and for whom
income tax, employment insurance and CPP deductions must be made at source);

 

		(ii)	works full-time for an Issuer or its subsidiary providing services normally provided by an employee and
who is subject to the same control and direction by the Issuer over the details and methods of work as an employee of the Issuer, but
for whom income tax deductions are not made at source; or

 

    D-1

     

    

 

		(iii)	works for an Issuer or its subsidiary on a continuing and regular basis for a minimum amount of time per
week (the number of hours should be disclosed in the submission) providing services normally provided by an employee and who is subject
to the same control and direction by the Issuer over the details and methods of work as an employee of the Issuer, but for whom income
tax deductions are not made at source;

 

		(k)	“Exchange” means the Canadian Securities Exchange and any successor entity;

 

		(l)	“Expiry Date” means the last day of the term for an Option, as set by the Board at
the time of grant in accordance with Section 5.2 and, if applicable, as amended from time to time;

 

		(m)	“Insider” means in respect of the Corporation: (a) a Director or senior officer of
the Corporation, (b) a Director or senior officer of a Company that is an Insider or subsidiary of the Corporation; (c) a Person that
beneficially owns or controls, directly or indirectly, Common Shares carrying more than 10% of the voting rights attached to all outstanding
Common Shares of the Corporation, or (d) the Corporation itself if it holds any of its own securities;

 

		(n)	“Investor Relations Activities” means any activities, by or on behalf of an Corporation
or shareholder of the Corporation, that promote or reasonably could be expected to promote the purchase or sale of securities of the Corporation,
but does not include:

 

		(i)	the dissemination of information provided, or records prepared, in the ordinary course of business of
the Corporation:

 

		(A)	to promote the sale of products or services of the Corporation; or

 

		(B)	to raise public awareness of the Corporation, that cannot reasonably be considered to promote the purchase
or sale of securities of the Corporation;

 

		(ii)	activities or communications necessary to comply with the requirements of:

 

		(A)	applicable securities laws;

 

		(B)	Exchange requirements or the by-laws, rules or other regulatory instruments of any other self regulatory
body or exchange having jurisdiction over the Corporation;

 

		(iii)	communications by a publisher of, or writer for, a newspaper, magazine or business or financial publication,
that is of general and regular paid circulation, distributed only to subscribers to it for value or to purchasers of it, if:

 

		(A)	the communication is only through the newspaper, magazine or publication; and

 

		(B)	the publisher or writer receives no commission or other consideration other than for acting in the capacity
of publisher or writer; or

 

		(iv)	activities or communications that may be otherwise specified by the Exchange;

 

		(o)	“Management Company Employee” means an individual who is employed by a person providing
management services to the Corporation or an Affiliate which are required for the ongoing successful operation of the business enterprise
of the Corporation or the Affiliate, but excluding a person providing Investor Relations Activities;

 

		(p)	“Officer” means an officer of the Corporation or of an Affiliate, and includes a Management
Company Employee;

 

		(q)	“Option” means an option to purchase Common Shares pursuant to this Plan;

 

		(r)	“Option Agreement” means an agreement, in the form attached hereto as Schedule “A”,
whereby the Corporation grants to an Eligible Persons an Option.

 

    D-2

     

    

 

		(s)	“Other Share Compensation Arrangement” means, other than this Plan and any Options,
any stock option plan, stock options, employee stock purchase plan or other compensation or incentive mechanism involving the issuance
or potential issuance of Common Shares, including but not limited to a purchase of Common Shares from treasury which is financially assisted
by the Corporation by way of loan, guarantee or otherwise;

 

		(t)	“Participant” means an Eligible Person who has been granted an Option; and

 

		(u)	“Plan” means this Stock Option Plan.

 

		1.2	INTERPRETATION

 

		(v)	References to the outstanding Common Shares at any point in time shall be computed on a non-diluted basis.

 

ARTICLE 2 – ESTABLISHMENT OF PLAN

 

		2.1	PURPOSE

 

The purpose of this Plan is to advance
the interests of the Corporation, through the grant of Options, by:

 

		(a)	providing an incentive mechanism to foster the interest of Eligible Persons in the success of the Corporation
and its Affiliates;

 

		(b)	encouraging Eligible Persons to remain with the Corporation or its Affiliates; and

 

		(c)	attracting new Directors, Officers, Employees and Consultant.

 

		2.2	SHARES RESERVED

 

		(d)	The aggregate number of Common Shares that may be reserved for issuance pursuant to Options shall not
exceed 5,905,000. For greater certainty, if an Option is surrendered, terminated or expires without being exercised, the Common Shares
reserved for issuance pursuant to such Option shall be available for new Options granted under this Plan.

 

		(e)	If there is a change in the outstanding Common Shares by reason of any share consolidation or split, reclassification
or other capital reorganization, or a stock dividend, arrangement, amalgamation, merger or combination, or any other change to, event
affecting, exchange of or corporate change or transaction affecting the Common Shares, the Board shall make, as it shall deem advisable
and subject to the requisite approval of the relevant regulatory authorities, appropriate substitution and/or adjustment in:

 

		(i)	the number and kind of shares or other securities or property reserved or to be allotted for issuance
pursuant to this Plan;

 

		(ii)	the number and kind of shares or other securities or property reserved or to be allotted for issuance
pursuant to any outstanding unexercised Options, and in the exercise price for such shares or other securities or property; and

 

		(iii)	the vesting of any Options (subject to the approval of the Exchange if such vesting is mandatory under
the policies of the Exchange), including the accelerated vesting thereof on conditions the Board deems advisable,

 

and if the Corporation undertakes an
arrangement or is amalgamated, merged or combined with another corporation, the Board shall make such provision for the protection of
the rights of Participants as it shall deem advisable.

 

		(f)	No fractional Common Shares shall be reserved for issuance under this Plan and the Board may determine
the manner in which an Option, insofar as it relates to the acquisition of a fractional Common Share, shall be treated.

 

		(g)	The Corporation shall, at all times while this Plan is in effect, reserve and keep available such number
of Common Shares as will be sufficient to satisfy the requirements of this Plan.

 

    D-3

     

    

 

		2.3	NON-EXCLUSIVITY

 

Nothing contained herein shall prevent the Board
from adopting such other incentive or compensation arrangements as it shall deem advisable.

 

		2.4	EFFECTIVE DATE

 

This Plan shall be subject to the approval of
any regulatory authority whose approval is required, if any. Any Options granted under this Plan prior to such approvals being given,
if required, shall be conditional upon such approvals being given, and no such Options may be exercised unless and until such approvals
are given. If no such approvals are required then this Plan is effective on the date it is approved by the Board.

 

ARTICLE 3 – ADMINISTRATION OF PLAN

 

		3.1	ADMINISTRATION

 

		(a)	This Plan shall be administered by the Board. Subject to the provisions of this Plan, the Board shall
have the authority:

 

		(i)	to determine the Eligible Persons to whom Options are granted, to grant such Options, and to determine
any terms and conditions, limitations and restrictions in respect of any particular Option grant, including but not limited to the nature
and duration of the restrictions, if any, to be imposed upon the acquisition, sale or other disposition of Common Shares acquired upon
exercise of the Option, and the nature of the events and the duration of the period, if any, in which any Participant’s rights in
respect of an Option or Common Shares acquired upon exercise of an Option may be forfeited;

 

		(ii)	to interpret the terms of this Plan, to make all such determinations and take all such other actions in
connection with the implementation, operation and administration of this Plan, and to adopt, amend and rescind such administrative guidelines
and other rules and regulations relating to this Plan, as it shall from time to time deem advisable, including without limitation for
the purpose of ensuring compliance with Section 3.3 hereof.

 

		(b)	The Board’s interpretations, determinations, guidelines, rules and regulations shall be conclusive
and binding upon the Corporation, Eligible Persons, Participants and all other persons.

 

		3.2	AMENDMENT, SUSPENSION AND TERMINATION

 

The Board may amend, subject to the approval of
any regulatory authority whose approval is required, suspend or terminate this Plan or any portion thereof. No such amendment, suspension
or termination shall alter or impair any outstanding unexercised Options or any rights without the consent of such Participant. If this
Plan is suspended or terminated, the provisions of this Plan and any administrative guidelines, rules and regulations relating to this
Plan shall continue in effect for the duration of such time as any Option remains outstanding.

 

		3.3	COMPLIANCE WITH LEGISLATION

 

		(a)	This Plan, the grant and exercise of Options hereunder and the Corporation’s obligation to sell,
issue and deliver any Common Shares upon exercise of Options shall be subject to all applicable federal, provincial and foreign laws,
policies, rules and regulations, to the policies, rules and regulations of any stock exchanges or other markets on which the Common Shares
are listed or quoted for trading and to such approvals by any governmental or regulatory agency as may, in the opinion of counsel to the
Corporation, be required. The Corporation shall not be obligated by the existence of this Plan or any provision of this Plan or the grant
or exercise of Options hereunder to sell, issue or deliver Common Shares upon exercise of Options in violation of such laws, policies,
rules and regulations or any condition or requirement of such approvals.

 

		(b)	No Option shall be granted and no Common Shares sold, issued or delivered hereunder where such grant,
sale, issue or delivery would require registration or other qualification of this Plan or of the Common Shares under the securities laws
of any foreign jurisdiction, and any purported grant of any Option or any sale, issue and delivery of Common Shares hereunder in violation
of this provision shall be void. In addition, the Corporation shall have no obligation to sell, issue or deliver any Common Shares hereunder
unless such Common Shares shall have been duly listed, upon official notice of issuance, with all stock exchanges on which the Common
Shares are listed for trading.

 

    D-4

     

    

 

		(c)	Common Shares sold, issued and delivered to Participants pursuant to the exercise of Options shall be
subject to restrictions on resale and transfer under applicable securities laws and the requirements of any stock exchanges or other markets
on which the Common Shares are listed or quoted for trading, and any certificates representing such Common Shares shall bear, as required,
a restrictive legend in respect thereof.

 

ARTICLE 4 – OPTION GRANTS

 

		4.1	ELIGIBILITY AND MULTIPLE GRANTS

 

Options shall only be granted to Eligible Persons.
An Eligible Person may receive Options on more than one occasion and may receive separate Options, with differing terms, on any one or
more occasions.

 

		4.2	OPTION AGREEMENT

 

Every Option shall be evidenced by an Option Agreement
executed by the Corporation and the Participant, which shall, if the Participant is an Employee, Consultant or Management Company Employee,
contain a representation and warranty by the Corporation and such Participant that such Participant is a bona fide Employee, Consultant
or Management Company Employee, as the case may be, of the Corporation or an Affiliate. In the event of any discrepancy between this Plan
and an Option Agreement, the provisions of this Plan shall govern.

 

		4.3	LIMITATION ON GRANTS AND EXERCISES

 

		(a)	Compliance with Securities Laws. All grants of Options under this Plan will comply with Section
2.25 of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”) as if the Corporation were an
“unlisted reporting issuer”.

 

		(b)	To any one person. The number of Common Shares reserved for issuance to any one person in any 12
month period under this Plan and any Other Share Compensation Arrangement shall not exceed 5% of the outstanding Common Shares at the
time of the grant, unless the Corporation has obtained Disinterested Shareholder Approval to exceed such limit as required by Section
2.25(3) of NI 45-106.

 

		(c)	To Consultants. The number of Common Shares reserved for issuance to any one Consultant in any
12 month period under this Plan and any Other Share Compensation Arrangement shall not exceed 2% of the outstanding Common Shares at the
time of the grant.

 

		(d)	To persons conducting Investor Relations Activities. The aggregate number of Common Shares reserved
for issuance to all Eligible Persons conducting Investor Relations Activities in any 12 month period under this Plan and any Other Share
Compensation Arrangement shall not exceed 2% of the outstanding Common Shares at the time of the grant.

 

		(e)	To Insiders. Unless the Corporation has received Disinterested Shareholder Approval to do so:

 

		(i)	the aggregate number of Common Shares reserved for issuance to Insiders under this Plan and any Other
Share Compensation Arrangement shall not exceed 10% of the outstanding Common Shares at the time of the grant;

 

		(ii)	the aggregate number of Common Shares reserved for issuance to Insiders in any

 

12 month period under this Plan and
any Other Share Compensation Arrangement shall not exceed 10% of the outstanding Common Shares at the time of the grant.

 

		(f)	Exercises. Unless the Corporation has received Disinterested Shareholder Approval to do so, the
number of Common Shares issued to any Eligible Person within a 12 month period pursuant to the exercise of Options granted under this
Plan and any Other Share Compensation Arrangement shall not exceed 5% of the outstanding Common Shares at the time of the exercise.

 

    D-5

     

    

 

ARTICLE 5 – OPTION TERMS

 

		5.1	EXERCISE PRICE

 

		(a)	The Corporation must not grant Options with an exercise price lower than the greater of the closing market
prices of the underlying securities on: (a) the trading day prior to the date of grant of the Options; and (b) the date of grant of the
Options.

 

		(b)	If an Option is granted by the Corporation after its initial listing or after it has been recalled for
trading following a suspension or halt, the Corporation must wait until a satisfactory market has been established before setting the
exercise price for and granting the option, being at least ten trading days since the date of listing or the day on which trading in the
Company’s securities resumes, as the case may be.

 

		(c)	If Options are granted within ninety days of a distribution by the Corporation by prospectus, then the
exercise price per Common Share for such Option shall not be less than the greater of the minimum exercise price calculated pursuant to
subsection (a) herein and the price per Common Share paid by the public investors for Common Shares acquired pursuant to such distribution.
Such ninety day period shall begin:

 

		(i)	on the date the final receipt is issued for the final prospectus in respect of such distribution;

 

		(ii)	in the case of an IPO, on the date of listing; and

 

		(iii)	in the case of a prospectus that qualifies special warrants, on the closing date of the private placement
in respect of such special warrants.

 

		5.2	EXPIRY DATE

 

		(a)	Every Option shall have a term not exceeding and shall therefore expire no later than 10 years after the
date of grant, subject to extension where the Expiry Date falls within a blackout period as detailed in Section 5.2(b) below.

 

		(b)	The Expiry Date of an Option shall automatic extend if such Expiry Date falls within a period (a “blackout
period”) during which an the Corporation prohibits Optionees from exercising their Options to the extent that:

 

		(i)	the blackout period is formally imposed by the Corporation pursuant to its internal trading policies as
a result of the bona fide existence of undisclosed Material Information. For greater certainty, in the absence of the Corporation formally
imposing a blackout period, the Expiry Date of any Options will not be automatically extended in any circumstances;

 

		(ii)	the blackout period must expire upon the general disclosure of the undisclosed Material Information. The
Expiry Date of the affected Options can be extended to no later than ten (10) business days after the expiry of the blackout period; and

 

		(iii)	the automatic extension of an Optionee’s Options will not be permitted where the Optionee or the
Corporation is subject to a cease trade order (or similar order under securities laws) in respect of the Corporation’s securities.

 

		5.3	VESTING

 

		(a)	Subject to the subsection (b) herein and otherwise in compliance with the policies of the Exchange, the
Board shall determine the manner in which an Option shall vest and become exercisable.

 

		(b)	Options granted to Eligible Persons performing Investor Relations Activities shall vest over a minimum
of 12 months with no more than 1/4 of such Options vesting in any 3 month period.

 

		5.4	NON-ASSIGNABILITY

 

Options may not be assigned or transferred.

 

    D-6

     

    

 

		5.5	CEASING TO BE ELIGIBLE PERSON

 

		(a)	If a Participant who is an Officer, Employee or Consultant is terminated for cause, each Option held by
such Participant shall terminate and shall therefore cease to be exercisable upon such termination for cause.

 

		(b)	If a Participant dies prior to otherwise ceasing to be an Eligible Person, each Option held by such Participant
shall terminate and shall therefore cease to be exercisable no later than the earlier of the Expiry Date and the date which is six months
after the date of the Participant’s death, always provided that the Board may, in its discretion, extend the date of such termination
and the resulting period in which such Option remains exercisable to a date not exceeding the earlier of the Expiry Date and the date
which is twelve months after the date of the Participant’s death.

 

		(c)	If a Participant ceases to be an Eligible Person other than in the circumstances set out in subsection
(a) or (b) herein, each Option held by such Participant shall terminate and shall therefore cease to be exercisable no later than the
earlier of the Expiry Date and the date which is 30 days after such event, always provided that the Board may, in its discretion, extend
the date of such termination and the resulting period in which such Option remains exercisable to a date not exceeding the earlier of
the Expiry Date and the date which is twelve months after such event, and further provided that the Board may, in its discretion, on a
case-by-case basis and only with the approval of the Exchange, further extend the date of such termination and the resulting period in
which such Option remains exercisable to a date exceeding the date which is after twelve months of such event.

 

		(d)	For greater certainty, if a Participant dies, each Option held by such Participant shall be exercisable
by the legal representative of such Participant until such Option terminates and therefore ceases to be exercisable pursuant to the terms
of Section 5.5(b).

 

		(e)	If any portion of an Option is not vested at the time a Participant ceases, for any reason whatsoever,
to be an Eligible Person, such unvested portion of the Option may not be thereafter exercised by the Participant or its legal representative,
as the case may be, always provided that the Board may, in its discretion further and subject to the approval of the Exchange where the
vesting of the said Participant’s options was a requirement of the Exchange’s policies, thereafter permit the Participant
or its legal representative, as the case may be, to exercise all or any part of such unvested portion of the Option that would have vested
prior to the time such Option otherwise terminates and therefore ceases to be exercisable pursuant to the terms of this Section. For greater
certainty, and without limitation, this provision will apply regardless of whether the Participant ceased to be an Eligible Person voluntarily
or involuntarily, was dismissed with or without cause, and regardless of whether the Participant received compensation in respect of dismissal
or was entitled to a notice of termination for a period which would otherwise have permitted a greater portion of an Option to vest.

 

ARTICLE 6 – EXERCISE PROCEDURE

 

		6.1	EXERCISE PROCEDURE

 

An Option may be exercised from time to time,
and shall be deemed to be validly exercised by the Participant only upon the Participant’s delivery to the Corporation at its registered
office:

 

		(a)	a written notice of exercise, in the form hereto attached as Schedule “B”, addressed to the
Corporate Secretary of the Corporation, specifying the number of Common Shares with respect to which the Option is being exercised;

 

		(b)	the originally signed Option Agreement with respect to the Option being exercised;

 

		(c)	a certified cheque or bank draft made payable to the Corporation for the aggregate exercise price for
the number of Common Shares with respect to which the Option is being exercised;

 

		(d)	documents containing such representations, warranties, agreements and undertakings, including such as
to the Participant’s future dealings in such Common Shares, as counsel to the Corporation reasonably determines to be necessary
or advisable in order to comply with or safeguard against the violation of the laws of any jurisdiction; and

 

		(e)	if the Participant is performing Investor Relations Activities for the Corporation, the Optionee must
either: (i) deposit the Common Shares on exercise of an Option to a designated brokerage account as directed by the Board through which
the Optionee conducts all trades in the Common Shares of the Corporation; or (ii) file insider trade reports with the Board when each
trade is made with Common Shares in respect of exercised Options,

 

and on the business day following, the Participant
shall be deemed to be a holder of record of the Common Shares with respect to which the Option is being exercised, and thereafter the
Corporation shall, within a reasonable amount of time, cause certificates for such Common Shares to be issued and delivered to the Participant.

 

    D-7

     

    

 

ARTICLE 7 – AMENDMENT OF OPTIONS

 

		1.1	CONSENT TO AMEND

 

The Board may amend any Option with the consent
of the affected Participant and the Exchange, including any shareholder approval required by the Exchange. For greater certainty, Disinterested
Shareholder Approval is required for any reduction in the exercise price of an Option if the Participant is an Insider at the time of
the proposed amendment.

 

		1.2	AMENDMENT SUBJECT TO APPROVAL

 

If the amendment of an Option requires regulatory
or shareholder approval, such amendment may be made prior to such approvals being given, but no such amended Options may be exercised
unless and until such approvals are given.

 

ARTICLE 8 – MISCELLANEOUS

 

		8.1	NO RIGHTS AS SHAREHOLDER

 

Nothing in this Plan or any Option shall confer
upon a Participant any rights as a shareholder of the Corporation with respect to any of the Common Shares underlying an Option unless
and until such Participant shall have become the holder of such Common Shares upon exercise of such Option in accordance with the terms
of the Plan.

 

		8.2	NO RIGHT TO EMPLOYMENT

 

Nothing in this Plan or any Option shall confer
upon a Participant any right to continue in the employ of the Corporation or any Affiliate or affect in any way the right of the Corporation
or any Affiliate to terminate the Participant’s employment, with or without cause, at any time; nor shall anything in the Plan or
any Option be deemed or construed to constitute an agreement, or an expression of intent, on the part of the Corporation or any Affiliate
to extend the employment of any Participant beyond the time which the Participant would normally be retired pursuant to the provisions
of any present or future retirement plan of the Corporation or any Affiliate, or beyond the time at which he would otherwise be retired
pursuant to the provisions of any contract of employment with the Corporation or any Affiliate.

 

		8.3	GOVERNING LAW

 

This Plan, all Option Agreements, the grant and
exercise of Options hereunder, and the sale, issue and delivery of Common Shares hereunder upon exercise of Options shall be, as applicable,
governed by and construed in accordance with the laws of the Province of British Columbia and the federal laws of Canada applicable therein.
The Courts of the Province of British Columbia shall have the exclusive jurisdiction to hear and decide any disputes or other matters
arising herefrom.

 

		8.4	SUB PLAN FOR PARTICIPANTS SUBJECT TO ISRAELI TAXATION

 

Any Participants who are resident in Israel shall
be subject to the Sub Plan attached hereto as Appendix "A" (the “102 Plan”). For greater certainty any issuances
to Participants subject to the 102 Plan shall only be issuable provided they do not contradict the regulations of the Exchange.

 

		8.5	APPROVAL

 

Approved by the Board of the Corporation on August
4, 2021.

 

 

D-8Exhibit 4.10

 

EXHIBIT A-1

 

SERIES A-1 COMMON STOCK
PURCHASE WARRANT

 

AGILE THERAPEUTICS, INC.

 

	Warrant Shares: _______	 	Initial Exercise Date: July ___, 2022

 

THIS SERIES A-1 COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July _____1
(the “Termination Date”) but not thereafter, to subscribe for and purchase from Agile Therapeutics, Inc.,
a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).

 

Section 1.              Definitions.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid Price”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.

 

 

1 Insert the date that is the 5 year anniversary of the
Initial Exercise Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.

 

    1

     

    

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee” 
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Registration
Statement” means the Company’s registration statement on Form S-1 (File No. 333-264960).

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).

 

    2

     

    

 

“Transfer
Agent” means Broadridge Corporate Issuer Solutions, Inc., the current transfer agent of the Company, with a mailing address
of 51 Mercedes Way, Edgewood, New York 11717, and any successor transfer agent of the Company.

  

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New
York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.

 

“Warrants”
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.

 

Section 2.              Exercise.

 

a)            Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn
on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and
the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within
three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The
Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.

 

    3

     

    

 

b)            Exercise
Price. The exercise price per share of Common Stock under this Warrant shall be $_____, subject to adjustment hereunder (the “Exercise
Price”).

 

c)            Cashless
Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

(A) = as
applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both
executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours”
(as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at
the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”)
as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular
trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after
the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on
the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is
both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such
Trading Day;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) = the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.

 

    4

     

    

 

If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take
any position contrary to this Section 2(c).

 

		d)	Mechanics of Exercise.

 

		i.	Delivery of Warrant Shares Upon Exercise.
                                            The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
                                            Agent to the Holder by crediting the account of the Holder’s or its designee’s
                                            balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian
                                            system (“DWAC”) if the Company is then a participant in such system and
                                            either (A) there is an effective registration statement permitting the issuance of the
                                            Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being
                                            exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered
                                            in the Company’s share register in the name of the Holder or its designee, for the
                                            number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
                                            address specified by the Holder in the Notice of Exercise by the date that is the earlier
                                            of (A) the earlier of (i) two (2) Trading Days and (ii) the number of
                                            days comprising the Standard Settlement Period, in each case after the delivery to the Company
                                            of the Notice of Exercise and (B) one (1) Trading Day after delivery of the aggregate
                                            Exercise Price to the Company (such date, the “Warrant Share Delivery Date”).
                                            Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
                                            to have become the holder of record of the Warrant Shares with respect to which this Warrant
                                            has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
                                            that payment of the aggregate Exercise Price (other than in the case of a cashless exercise)
                                            is received by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash,
                                            as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
                                            such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
                                            of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading
                                            Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
                                            Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
                                            Company agrees to maintain a transfer agent that is a participant in the FAST program so
                                            long as this Warrant remains outstanding and exercisable. As used herein, “Standard
                                            Settlement Period” means the standard settlement period, expressed in a number
                                            of Trading Days, on the Company’s primary Trading Market with respect to the Common
                                            Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the
                                            foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00
                                            p.m. (New York City time) on the Business Day before the Initial Exercise Date, which
                                            may be delivered at any time after May __, 20222,
                                            the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New
                                            York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant
                                            Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery
                                            Date.

 

    5

     

    

 

ii.            Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

iii.           Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.           Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action by
the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of
the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have
been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock
with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.

 

 

2 To be dated the date of the Securities Purchase Agreement

 

    6

     

    

 

v.            No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

vi.           Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.          Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    7

     

    

 

e)            Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.  Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination
(including any determination as to group status pursuant to the next sentence). In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon the written
or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number
of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or
Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise
of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.

 

    8

     

    

 

Section 3.              Certain
Adjustments.

 

a)            Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)            Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    9

     

    

 

c)            Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).

 

    10

     

    

 

d)            Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise
of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise
of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction,
the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with,
or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable
Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction;
provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by
the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or
form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being
offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration
be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from
among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock
will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction)
in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black Scholes
Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate
for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and
the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement
of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the
greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any,
being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately
preceding the announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section 3(d) and (D) a
remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of
immediately available funds within five (5) Trading Days of the Holder’s election (or, if later, on the effective date of
the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the
survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and
the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and
shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if
such Successor Entity had been named as the Company herein.

 

    11

     

    

 

e)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

f)             Notice
to Holder.

 

i.             Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.            Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all
or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.
The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date
of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    12

     

    

 

g)            Voluntary
Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term
of this Warrant, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors.

 

Section 4.              Transfer
of Warrant.

 

a)            Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.

 

b)            New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)            Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

    13

     

    

 

Section 5.              Miscellaneous.

 

a)            No
Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.

 

b)            Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)            Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading
Day.

 

d)            Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

 

    14

     

    

 

Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

e)            Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys’
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

    15

     

    

 

f)             Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g)            Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h)            Notices.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Company, at ___________, Attention: ___________, email address: ___________, or such other email address or address
as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be
provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice
or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New
York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication is delivered
via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that
any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.

 

i)             Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

    16

     

    

 

j)             Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k)            Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

l)             Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.

 

m)           Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n)            Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.

 

********************

 

(Signature Page Follows)

 

    17

     

    

 

IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	AGILE THERAPEUTICS, INC.
	 	 
	 	 
	 	By:	                     
	 	Name:
	 	Title:

 

    18

     

    

 

NOTICE OF EXERCISE

 

To:         aGILE
THERAPEUTICS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[ ] in lawful money of the United States;
or

 

[ ] if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

The Warrant Shares shall be delivered to the
following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name of Investing Entity: _____________________________________________________________________________________________________

Signature of Authorized Signatory of Investing
Entity: _______________________________________________________________________________

Name of Authorized Signatory: _________________________________________________________________________________________________

Title of Authorized Signatory: __________________________________________________________________________________________________

Date: ______________________________________________________________________________________________________________________

 

    

     

    

 

ASSIGNMENT FORM

  

(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to

 

	Name:	
	 	(Please Print)
	 	 
	Address:	
	

    
	(Please Print)

    

    

	 	 
	Phone Number:	 
	 	 
	Email Address: 	 
	 	 
	Dated: _______________ __, ______	 
	 	 
	Holder’s Signature: _________________________________ 	 
	 	 
	Holder’s Address:  _________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]